Verastem

Verastem ROIC

The Return on Invested Capital (ROIC) of Verastem (VSTM) as of Nov 5, 2026 is -150.63 %. In the previous year, Return on Invested Capital (ROIC) was -1,104.19 % — a change of -86.36% (higher).

ROIC

-150.63 %

YoY

-86.36%

Last updated:

Return on Invested Capital (ROIC) of Verastem is 2025 -150.63 % . Return on Invested Capital (ROIC) of Verastem was 2024 -1,104.19 % . It decreases by -86.36% higher compared to the previous year.

The Verastem ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-29.59 USD
Jan 1, 2019
-134.70 USD
Jan 1, 2020
-50.40 USD
Jan 1, 2021
-81.13 USD
Jan 1, 2022
-102.25 USD
Jan 1, 2023
-89.64 USD
Jan 1, 2024
-1,104.19 USD
Jan 1, 2025
-150.63 USD
The Verastem ROIC history
YEARROICYoY
-150.63 %-86.36%
-1,104.19 %+1,131.75%
-89.64 %-12.32%
-102.25 %+26.02%
-81.13 %+60.97%
-50.40 %-62.58%
-134.70 %+355.22%
-29.59 %-68.37%
-93.54 %+85.58%
-50.40 %-10.74%
-56.47 %-6.07%
-60.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Verastem Stock analysis

What does Verastem do? Verastem Oncology develops and commercializes oncology drugs to improve cancer patient survival and quality of life. The company focuses on defactinib, an oral small molecule inhibitor of FAK and PYK2, and VS-6766, a RAF/MEK pathway inhibitor. Defactinib is being evaluated for combination therapy in solid tumors, while VS-6766 blocks MEK kinase activity and RAF phosphorylation. Verastem conducts clinical trials for cancers with limited treatment options including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer, and pancreatic cancer. The company markets and develops these products for healthcare providers and patients in the oncology segment. Verastem Oncology targets cancer patients requiring new treatment options, particularly in underserved areas like pancreatic cancer and mesothelioma. Its products are designed to address unmet medical needs in oncology through targeted therapies. Verastem generates revenue through the commercialization of defactinib and VS-6766 once approved. The company's business model relies on developing drugs for cancer treatment, with clinical trials focused on improving outcomes for patients with limited therapeutic options. Revenue streams come from product sales and potential partnerships for drug development and commercialization. Verastem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Verastem stock

Return on Invested Capital (ROIC) of Verastem is -150.63 % in 2025.

Return on Invested Capital (ROIC) of Verastem changed from -1,104.19 % to -150.63 %, representing a -86.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Verastem since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Verastem with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Verastem

All Key Metrics — Verastem